BNTX - BIONTECH SE SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BioNTech SE (NASDAQ: BNTX) | Benzinga
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
- Do you, or did you, own shares of BioNTech SE (NASDAQ:BNTX)?
- Did you purchase your shares between March 30, 2022 and October 13, 2023, inclusive?
- Did you lose money in your investment in BioNTech SE?
- Do you want to discuss your rights?
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of BioNTech SE ("BioNTech" or the "Company") (NASDAQ:ASRT) between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint").
If you purchased or acquired BioNTech securities, and/or would like to discuss your legal rights and options please visit BioNTech SE Shareholder Class Action Lawsuit or contact paralegal Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
According to the Complaint, BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases. The Company has developed and continues to develop, among other products and product candidates, Comirnaty, a COVID-19 vaccine, in collaboration with Pfizer Inc. ("Pfizer"). As part of ...
BNTX)>Full story available on Benzinga.com